3 Reasons to Watch Galena Biopharma Inc.'s Next Catalyst

With news flow being positive for Galena Biopharma Inc (GALE) in 2014, the next catalyst could be worth keeping an eye on

Jan 20, 2014 at 3:00PM

This has already been a busy and eventful year for Galena Biopharma (NASDAQ:GALE). The company has caught the eye of many health-care investors in the three weeks since the Champagne corks popped to welcome in the New Year. Shares have risen from under $5 each on Dec. 31 to their current price of $7 -- more than a 40% gain in just three weeks!

Three significant pieces of news flow seem to have been responsible:

1. Galena announced on Jan. 7 that the first patient had been enrolled in the Phase 2 trial for GALE-301, which is a folate binding protein with potential use in conjunction with an adjuvant to prevent recurrences in high-risk, endometrial and ovarian cancer patients. The market seemed to be positive about this development, as it showed that Galena's drug pipeline is making some advances.

2. On Jan. 13, Galena announced the acquisition of Mills Pharmaceuticals, a biopharmaceutical company that specializes in the development and commercialization of targeted oncology treatments. The main take-home feature of the acquisition is the addition of GALE-401, which is a patented, controlled-release formulation of anagrelide to be used for the treatment of essential thrombocythemia. Total sales from the drug are estimated to be worth up to $200 million per annum.

3. A strategic partnership between Galena and Dr. Reddy's Laboratories was announced on Jan. 14, which is focused on a commercialization partnership on NeuVax in India. The deal means that Galena has licensed commercial rights to Dr. Reddy's for NeuVax in breast and gastric cancers in India, with Galena receiving development and sales milestones as well as double-digit royalties on net sales.

Of course, the progress made with clinical trials is extremely difficult to ascertain. However, the reaction of the share price (up more than 40% in less than three weeks) indicates that market sentiment is strong and that further catalysts could be worth keeping a close eye out for during the rest of 2014.

Indeed, the positive impact of catalysts in other health care stocks has also been witnessed in 2014. An example is the strong support shown to Chelsea Therapeutics International's (NASDAQ:CHTP) Northera drug, which received a vote of 16-1 in favor by an FDA advisory committee.

Although the committee is there to do as its name suggests (i.e., to advise the FDA), its recommendations do tend to be followed by the FDA, and that's why shares in Chelsea Therapeutics pushed through $5 on the back of the news.

Similarly, Intercept Pharmaceuticals' (NASDAQ:ICPT) share price quadrupled after a clinical trial was halted early when patients taking a liver-disease drug had shown a "highly statistically significant improvement" in measures of the health of their liver versus a placebo.

Such catalysts, although unpredictable, inevitably have a major impact upon the share price of the company in question. Health-care investors may wish to keep an eye out for the next catalyst on Galena's horizon, which could be further developments surrounding the aforementioned GALE-301 Phase 2 trial, in which the first patient was enrolled just a couple of weeks ago.

The top stock for 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Fool contributor Peter Stephens and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers